Articles related to STIMULANTS

This study offers valuable insights into the safety of stimulant medication use during pregnancy, highlighting the need for nuanced patient counseling and consideration of individual risks and benefits in managing ADHD symptoms.

The study suggests that although unlicensed doses may lead to additional symptom reduction, the gains are small and come with an increased risk of adverse events.

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.

Discover how viloxazine ER could offer a new avenue for enhancing ADHD treatment efficacy in pediatric patients with inadequate response to stimulants.

The stimulant crisis is affecting ADHD treatment across the board; Dr. Greg Mattingly offers crucial insights into navigating this challenging landscape. Learn about alternative treatment options to better serve your patients.

Discover the latest advancements in ADHD therapies that promise greater efficacy and fewer side effects—options that can revolutionize personalized treatment plans.